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ABOUT THE JOURNAL 
 
 
Aims and Scope 
Oncogenesis is a peer-reviewed open access online journal 
that publishes full-length papers exploring the molecular 
basis of cancer and related phenomena. It seeks to promote 
diverse and integrated areas of molecular biology, cell 
biology, oncology, and genetics. 
 
Oncogenesis seeks to encompass the breadth of the 
molecular biology of malignant change, and topics of 
particular interest include:  
 Apoptosis 
 Cancer metabolism 
 Cell cycle and growth regulation 
 Cellular oncogenes 
 Cellular transformation and immortalization 
 DNA damage and repair 
 Mode of action of cancer therapeutics 
 Molecular oncology 
 Novel targeted therapies 
 Senescence 
 Tumour suppression 
 Virus-induced oncogenesis
Journal Details 
Editor-in-Chief:   
Jan Paul Medema 
University of Amsterdam, Netherlands 
 
Editorial office:  
Nature Publishing Group 
One New York Plaza, Suite 4500 
New York, NY 10004-1562 
oncogene@us.nature.com 
 
Impact factor: 3.952 (2014 Journal Citation Reports, 
Thomson Reuters, 2015) 
 
Abstracted/indexed in:  
MEDLINE/PubMed 
PubMed Central 
Scopus 
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ARTICLE TYPE SPECIFICATIONS 
 
 
Article Description Word Limit 
Original Articles (Please see ‘Preparation of Articles’ below for 
further details) 
Manuscripts describing novel experimental findings with 
more than four figures and/or tables. Keep the text as brief 
and clear as possible, and prepare figures to occupy a 
minimum of space.  
Full-length papers should not exceed a 
total of 4,500 words (excluding 
abstract, references and figure 
legends). Include the word count for 
your manuscript in your cover letter. 
 
 
Reviews 
Review articles are summaries of a large field of research. 
Submissions are typically by Editor invitation only; however, 
occasionally unsolicited Reviews may be considered. For any 
inquiries or to propose a Review topic for consideration, 
please contact the editorial office: oncogene@us.nature.com  
 
Review articles should not exceed 
6,000 words.  
 
Short Communications 
A short communication is a concise, independent report 
representing a significant and timely contribution to cancer 
biology. A short communication is not intended to publish 
preliminary results. The results must be of exceptional interest 
and relevant to be considered for publication. 
 
The text should be organized with an Introduction, and the 
Results and Discussion sections should be combined. All 
Materials and Methods should be included in the figure 
legends. The text must be succinctly written, and figures (no 
more than four) prepared to occupy a minimum of space. 
 
Short Communications should not 
exceed a total of 2,500 words 
(excluding the abstract, references and 
legends). Include a word count for 
your manuscript in your cover letter. 
 
Letters to the Editor 
Letters to the Editor will be considered for publication, subject 
to editing. Letters must contain information critical to a certain 
area or must be confirmatory of data recently published in 
Oncogenesis. 
 
Letters must reference the original source, and a Response to a 
Letter must reference the Letter in the first few paragraphs, as 
well as the original source. Letters can use an arbitrary title, 
but a Response must cite the title of the Letter: e.g. Response 
to [title of Letter]. 
 
All Letters must contain a title page including all authors’ 
names and affiliations and corresponding author contact 
information. 
 
Letters must not exceed 400 words (not 
including references). There is a limit 
of five references. The first reference 
must be the citation for the original 
article under discussion. 
 
Letters may contain figures or tables 
(up to two each) only if they show data 
that refute the original article’s 
conclusions. Figures or tables showing 
unpublished data in support of the 
original article’s conclusions will not 
be considered. 
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PREPARATION OF ARTICLES 
 
 
Articles must contain the following elements as outlined in the 
table above:  
 Cover letter (including a Conflict of interest statement) 
 Title page (excluding acknowledgments)  
 Abstract and keywords  
 Introduction  
 Results  
 Discussion 
 Materials and methods 
 Conflict of interest 
 Acknowledgments 
 References 
 Tables 
 Figures  
 
Cover Letter: The cover letter must state that the manuscript 
presents original research, has not been previously published, 
and is not being considered for publication elsewhere. The 
cover letter must also contain a Conflict of interest statement 
(see Editorial Policy section). Note that the cover letter will be 
visible to the reviewers of your paper. 
 
Title Page: The title page must include the title of the paper, the 
full names and affiliations of all authors, and the name, full 
postal address, telephone and fax numbers, and email address 
of the author to whom correspondence is to be sent. The title 
should be brief, informative, and written in 150 characters or 
less. It should not make a statement or conclusion about the 
findings of the paper. The running title (which will appear on 
subsequent pages should the paper be published in the journal) 
must consist of not more than 50 letters and spaces. It must be 
as brief as possible, conveying the essential message of the 
paper. Authors should disclose the sources of any support for 
the work, received in the form of grants, equipment, and/or 
drugs.  
Abstract and keywords: The abstract must not exceed 300 
words. Three to six descriptive keywords should be included to 
aid web searches after publication. 
 
Introduction: The Introduction should assume that the reader 
is knowledgeable in the field and should therefore be as brief as 
possible; however, it can include a short historical review 
where appropriate. 
 
Results: Results must briefly present the experimental data in 
text, tables, or figures. When tables and figures are used, they 
should not be described extensively in the text. 
 
Discussion: The Discussion must focus on the interpretation 
and the significance of the findings, with concise objective 
comments that describe their relation to other work in the area. 
It should not repeat information presented in the Results. The 
final paragraph should highlight the main conclusions and 
provide some indication of the direction future research should 
take. 
 
Materials and methods: Materials and methods must contain 
sufficient details, including references, so that all experimental 
procedures can be reproduced. Methods that have been 
published in detail elsewhere should not be described in detail; 
a reference to the original paper should be used instead. The 
Materials and methods section must be included within the 
main text of the manuscript and may not under any 
circumstances be included as supplementary information. 
 
Authors must provide the name of the manufacturer and its 
location for any named medical equipment and/or instruments. 
All drugs must be identified by their pharmaceutical names and 
by their trade name, if relevant. 
 
Conflict of interest: Authors must declare whether or not there 
are any competing financial interests in relation to the work 
described. This information must be included upon submission 
and will be published as part of the paper. Conflict of interest 
should also be noted in the cover letter. See the Conflict of 
interest section in Editorial Policy below for more information. 
 
Acknowledgments: Acknowledgments must be brief and 
include sources of support such as sponsorship (e.g. grants or 
other financial support received from universities or other 
academic institutions; corporations or other commercial entities; 
government agencies; non-governmental organization; 
charities) and sources of material (e.g. novel drugs, equipment) 
not available commercially. 
 
References: References must follow the Vancouver format. In 
the text, they should appear as numbers starting at 1 and at the 
end of the paper they should be listed (double-spaced) in 
numerical order corresponding to the order of citation in the 
text. All authors should be cited for papers with up to six 
authors; for papers with more than six authors, only the first six 
should be cited, followed by et al. Abbreviations for titles of 
periodicals should conform to those used in the latest edition of 
Index Medicus. The first and last page numbers for each 
reference should be provided. Abstracts and letters must be 
identified as such. Papers in press and papers already 
submitted for publication may be included (and indicated as 
such) in the reference list but no citation is required for work 
that is not yet submitted for publication. 
Journal article, up to six authors:  
1. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E et al. 
Prostate stem cell antigen: a cell surface marker overexpressed 
in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735–1740.  
Journal article, e-pub ahead of print: 
2. Glendenning J, Khoo V. Sweet's syndrome in prostate cancer. 
Prostate Cancer Prostatic Dis 2008; e-pub ahead of print 29 
January 2008; doi:10.1038/sj.pcan.4501029.  
Journal article, in press:  
3. Kao PF, Chou YH, Lai CW. Diffuse FDG uptake in acute 
prostatitis. Clin Nucl Med (in press).  
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Complete book:  
4. Burnet FM. Immunological Surveillance. Pergamon Press: 
Oxford, UK, 1970.  
Chapter in book:  
5. Denmeade SR, Isaacs JT. Activation of programmed 
(apoptotic) cell death for the treatment of prostate cancer. In: 
August JT, Anders MW, Murad F, Coyle JT (eds). Advances in 
Pharmacology, vol. 35. Academic Press: London, 1996, pp 281–
306.  
Abstract:  
6. Lennon S, Strong A. Wnt signaling and cancer development: 
therapeutic implications. Neoplasma 2006; 53 (Suppl 1): 123 
(abstract 456).  
Letter to the Editor:  
7. Braillon A. Re: is a screening interval of every 4 years for 
prostate cancer acceptable? [letter]. J Natl Cancer Inst 2008; 100: 
222–223.  
Personal communications must be allocated a number and 
included in the list of references in the usual way. Authors 
must obtain permission from the individual concerned to quote 
his/her unpublished work.  
 
Where a reference is next to a number (for example an 
equation, chemical formula, or biological acronym) instead of 
being put in superscript, e.g. bcl-23, it should be written as (ref. 
3). For example:  
 "that does not express bcl-2 (ref. 3) and subjected it to…" 
 "detectable levels of endogenous bcl-2 (ref. 3), as 
confirmed by western blot."  
 “dominant-negative inhibitor of bcl-2 (ref. 3). In this 
study…" 
 
Tables: Tables must be titled, numbered sequentially, and cited 
within the text. Present each table on its own page. Reference to 
table footnotes should be made by means of Arabic numerals. 
Tables should not duplicate the content of the text. They should 
consist of at least two columns; columns should always have 
headings. Ensure that the data in the tables are consistent with 
those cited in the relevant places in the text, totals add up 
correctly, and percentages have been calculated correctly. 
Unlike figures or images, tables may be included at the end of 
the text document or supplied as separate electronic files. 
 
Figures: Figures and images must be numbered sequentially 
and cited in the text. Figure legends should be brief, specific, 
and appear on a separate manuscript page after the References 
section. Do not embed figures within the text. If a figure has 
been published before, the authors must obtain written 
permission to reproduce the material in both print and 
electronic formats from the copyright owner and submit it with 
the manuscript. This follows for quotes, illustrations, data, 
tables, and any other material taken from previously published 
works not in the public domain. The original source must be 
cited in the figure caption or table footnote. The use of three-
dimensional histograms is strongly discouraged when the 
addition of the third dimension gives no extra information. For 
electron micrographs, use scale markers and indicate the type 
of stain used. Detailed guidelines for submitting artwork can be 
found by downloading the Artwork Guidelines.  
Supplementary Information: Supplementary information (SI) 
is peer-reviewed material directly relevant to the conclusion of 
an article that cannot be included in the article itself owing to 
space or format constraints. The article must be complete and 
self-explanatory without the SI, which is posted on the journal's 
website and linked to the article. SI may consist of data files, 
extensive tables, graphics, movies, or animations. View the 
Artwork Guidelines for more information on acceptable file 
types and sizes. Submit SI files in their final format as they are 
not edited, typeset, or changed—they will appear online exactly 
as submitted. When submitting SI files: 
 Include a text summary (no more than 50 words) 
describing the contents of each file 
 Identify the file format submitted 
 Include the text “Supplementary Information accompanies 
the paper on the Oncogenesis website 
(http://www.nature.com/oncsis)” at the end of the text and 
before the References. 
 
House Style 
 Do not make rules thinner than 1pt (0.36mm) 
 Use a coarse hatching pattern rather than shading for tints 
in graphs 
 Color should be distinct when being used as an identifying 
tool 
 Use spaces (not commas) to separate thousands 
 Define abbreviations upon first use 
 Use International System of Units (SI units) throughout 
 Double space text and use a wide margin 
 At first mention of a manufacturer, provide the town (and 
state if USA) and country 
 
Availability of Data and Materials: An inherent principle of 
publication is that others must be able to replicate and build 
upon the authors' published claims. Therefore, a condition of 
publication is that authors are required to make materials, data, 
and associated protocols available in a publicly accessible 
database (as detailed below). Where one does not exist, the 
information must be made available to referees upon 
submission and to readers promptly upon request. Any 
restrictions on materials availability or other relevant 
information must be disclosed in the manuscript’s Materials 
and methods section and should include details of how 
materials and information may be obtained.  
Sequences, structures, and 'omics': Papers reporting protein or 
DNA sequences and molecular structures will not be accepted 
without an accession number to Genbank, EMBL, DDBJ, Protein 
DataBank, SWISS-PROT, or other appropriate, identified, 
publicly available databases in general use in the field that gives 
free access to researchers from the date of publication.  
Authors of papers describing structures of biological 
macromolecules must provide experimental data upon the 
request of editors if they are not already freely accessible in a 
publicly available database such as Protein DataBank, Nucleic 
Acids Database, or Biological Magnetic Resonance Databank. 
Five separate copies of these data should be provided to the 
editors in an appropriate format for the purposes of peer 
review.  
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Language Editing 
Authors who are not native speakers of English sometimes 
receive negative comments from referees or editors about the 
language and grammar usage in their manuscripts, which can 
contribute to a paper being rejected. To reduce the possibility of 
such problems, we strongly encourage such authors to take at 
least one of the following steps: 
 Have your manuscript reviewed for clarity by a colleague 
whose native language is English. 
 Review the tips for technical writing on the Author Resources 
page. 
 Use an English language editing service such as Nature 
Publishing Group Language Editing. An editor will improve 
the English to ensure that your meaning is clear and to 
identify problems that require your review.  
 
Please note that the use of a language editing service is at the 
author's own expense and does not guarantee that the article will 
be selected for peer review or accepted.  
 
 
 
HOW TO SUBMIT 
 
 
Pre-submission Inquiries  
Please submit pre-submission inquiries via the online 
manuscript submission system or via e-mail to 
oncogene@us.nature.com. 
 
Online Submission 
We only accept manuscript submission via our online 
manuscript submission system. Before submitting a 
manuscript, authors are encouraged to consult both our 
Editorial Policies and the Submission Instructions for our 
online manuscript submission system. If you have not already 
done so, please register for an account with our online 
manuscript system. You will be able to monitor the status of 
your manuscript online throughout the editorial process.  
 
Submission of Revisions 
Authors submitting a revised manuscript after review are asked 
to include the following: 
(1) A letter indicating point-by-point how you have addressed 
the comments raised by the editors and reviewers. If you 
disagree with any of the points raised, please provide 
adequate justification in your letter.   
(2) A revised version of the manuscript that includes changes 
based on the comments raised by the editors and 
reviewers.  
 
 
POST-ACCEPTANCE 
 
 
Oncogenesis is an open access journal: authors pay an article 
processing charge (APC) for their accepted articles to be open 
access online and freely accessible, immediately upon publication, 
under a Creative Commons license. 
 
Visit our open research site for further information about licenses, 
APCs, and our free OA funding support service: 
 
 About Creative Commons licensing 
 Creative Commons license options and article processing 
charges (APCs) for Oncogenesis 
 APC payment FAQs 
 Help in identifying funding for APCs 
 APC waiver policy 
 Compliance with funding body requirements  
 
Once a manuscript is accepted the corresponding author must 
complete an Article Processing Charge (APC) payment form and 
an open access License to Publish (LTP) form on behalf of all 
authors, and return these to the editorial office. Forms will be 
provided upon acceptance of the article. Failure to promptly 
return forms will result in delay of publication. 
 
Government employees from the United States, UK and Canada 
are required to sign and submit the relevant government open 
access license to publish form. 
Please note with regards to payment that usual credit terms are 30 
days from receipt of invoice. Failure to pay your invoice within the 
stated credit term may result in such penalties as restrictions on 
your ability to publish with Nature Publishing Group or  Cell 
Death & Disease in the future, involvement of a third Party debt 
collection agency and legal proceedings. 
 
Manuscript deposition and self-archiving 
To facilitate self-archiving NPG deposits open access articles in 
PubMed Central and Europe PubMed Central on publication. 
Authors are also permitted to post the final, published PDF of 
their article on a website, institutional repository or other free 
public server, immediately on publication. Learn more about self-
archiving and deposition of papers published OA. 
 
Proofs 
The corresponding author will receive an e-mail containing a URL 
linking to the proofing site. Proof corrections must be returned 
within 48 hours of receipt. Failure to do so may result in delayed 
publication. Extensive corrections cannot be made at this stage. 
Protocol Exchange  
If your manuscript is accepted for publication, we encourage 
you to upload the step-by-step protocols used in your 
manuscript to the Protocol Exchange. Protocol Exchange is an 
open online resource that allows researchers to share their 
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detailed experimental know-how. All uploaded protocols are 
made freely available, assigned DOIs for ease of citation and 
fully searchable through nature.com. Protocols can be linked 
to any publications in which they are used and will be linked 
to from your article. You can also establish a dedicated page to 
collect all your lab Protocols. By uploading your Protocols to 
Protocol Exchange, you are enabling researchers to more 
readily reproduce or adapt the methodology you use, as well 
as increasing the visibility of your protocols and papers. 
Upload your protocols at the Protocol Exchange web site. 
Further information can be found here.  
 
 
COSTS 
 
 
Article Processing Charge 
Oncogenesis levies the following article processing charges 
(APC) for each article accepted for publication: 
£2,600/$3,500/€2,800 (plus VAT or local taxes where 
applicable). A payment form will need to be completed and 
returned alongside the License to Publish form. Failure to 
promptly return these forms will result in delay of publication.   
 
With regards to payment, usual credit terms are 30 days from 
receipt of invoice. Failure to pay your invoice within the stated 
credit term may result in restrictions on your ability to publish 
with Nature Publishing Group or Oncogenesis in the future, 
involvement of a third party debt collection agency, and legal 
proceedings. 
 
Fee waiver policy  
 
We offer APC waivers to authors from HINARI countries. 
Discretionary APC waivers will be considered on a case-by-
case basis and may be granted in cases of financial  
need. All applications for APC waivers should be made prior 
to, or at the point of, manuscript submission; requests made 
during the review process or after acceptance will not be 
considered. To request a waiver, please contact us at 
openaccess@nature.com. 
 
Open access funding 
NPG also offers an APC support service to make it easier for 
NPG authors to discover and apply for open access funding. 
For advice on what funding is available to you and help in 
approaching funders and institutions, please contact us at 
openaccess@nature.com. 
 
For more information about NPG's open access publishing 
options and policies, please see our open access homepage. 
 
 
EDITORIAL POLICIES 
 
 
Duplicate Publication 
Papers must be original and not published or submitted for 
publication elsewhere. This rule also applies to non-English 
language publications. NPG allows and encourages prior 
publication on recognized community preprint servers for 
review by other scientists before formal submission to 
Oncogenesis. The details of the preprint server concerned and 
any accession numbers should be included in the cover letter 
accompanying manuscript submission. This policy does not 
extend to preprints available to the media or that are otherwise 
publicized outside the scientific community before or during 
the submission and review process. 
 
Permissions 
If a table or figure has been published before, the authors must 
obtain written permission to reproduce the material in both 
print and electronic formats from the copyright owner and 
submit it with the manuscript. This follows for quotes, 
illustrations, data, tables, and any other material taken from 
previously published works not in the public domain. The 
original source must be cited in the figure caption or table 
footnote. 
 
Clinical Trials 
As defined by the International Committee of Medical Journal 
Editors (ICMJE), a clinical trial is any research project that 
prospectively assigns human subjects to intervention and 
comparison groups to study the cause-and-effect relationship 
between a medical intervention and a health outcome. A 
medical intervention is any intervention used to modify a 
health outcome and includes but is not limited to drugs, 
surgical procedures, devices, behavioural treatments, and 
process-of-care changes. A trial must have at least one 
prospectively assigned concurrent control or comparison group 
in order to trigger the requirement for registration. 
Nonrandomized trials are not exempt from the registration 
requirement if they meet the above criteria. 
 
When reporting experiments on human subjects, please indicate 
whether the procedures were in accordance with the ethical 
standards of the responsible committee on human 
experimentation (institutional or regional) or with the Helsinki 
Declaration of 1975 (as revised in 1983).  Include Institutional 
Review Board or Animal Care and Use Committee approvals. 
 
All clinical trials must be registered in a public registry prior to 
submission. The journal follows the trials registration policy of 
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the ICMJE (www.icmje.org) and considers only trials that have 
been appropriately registered before submission, regardless of 
when the trial closed to enrolment. Acceptable registries must 
meet the following ICMJE requirements:  
 be publicly available, searchable, and open to all 
prospective registrants  
 have a validation mechanism for registration data  
 be managed by a not-for-profit organization  
 
Examples of registries that meet these criteria include:  
1) the registry sponsored by the United States National 
Library of Medicine, www.clinicaltrials.gov;  
2) the International Standard Randomized Controlled Trial 
Number Registry, www.controlled-trials.com;  
3) the Cochrane Renal Group Registry, www.cochrane-
renal.org;  
4) and the European Clinical Trials Database, 
https://eudract.ema.europa.eu/. 
 
The trial registry number for eligible papers will be collected 
during the submission process. 
 
Randomised Controlled Trials (RCTs) must adhere to the 
CONSORT statement, (CONsolidated Standards Of Reporting 
Trials) and submissions must be accompanied by a completed 
CONSORT checklist (uploaded as a related manuscript file). 
Further information can be found at www.consort-
statement.org.  
  
Nature Publishing Group endorses the toolkits and guidelines 
produced by the Committee on Publication Ethics, 
http://publicationethics.org/. 
 
Conflict of Interest 
In the interests of transparency and to help readers form their 
own judgments of potential bias, authors must declare whether 
or not there are any competing financial interests in relation to 
the work described. This information must be included in their 
cover letter and on the title page of their manuscript. In cases 
where the authors declare a competing financial interest, a 
statement to that effect is published as part of the article. If no 
such conflict exists, the statement will simply read that the 
authors have nothing to disclose. 
 
For the purposes of this statement, competing interests are 
defined as those of a financial nature that, through their 
potential influence on behaviour or content, or from perception 
of such potential influences, could undermine the objectivity, 
integrity or perceived value of a publication. They can include 
any of the following:  
 Funding: Research support (including salaries, equipment, 
supplies, reimbursement for attending symposia, and 
other expenses) by organizations that may gain or lose 
financially through this publication. The role of the 
funding body in the design of the study, collection and 
analysis of data and decision to publish should be stated. 
 Employment: Recent (while engaged in the research 
project), present or anticipated employment by any 
organization that may gain or lose financially through this 
publication. 
 Personal financial interests: Stocks or shares in companies 
that may gain or lose financially through publication; 
consultation fees or other forms of remuneration from 
organizations that may gain or lose financially; patents or 
patent applications whose value may be affected by 
publication.  
 
It is difficult to specify a threshold at which a financial interest 
becomes significant, but note that many US universities require 
faculty members to disclose interests exceeding $10,000 or 5% 
equity in a company. Any such figure is arbitrary, so we offer as 
one possible practical alternative guideline: "Declare all 
interests that could embarrass you were they to become 
publicly known after your work was published." We do not 
consider diversified mutual funds or investment trusts to 
constitute a competing financial interest.  
 
The statement must contain an explicit and unambiguous 
statement describing any potential conflict of interest, or lack 
thereof, for any of the authors as it relates to the subject of the 
report. Examples include “Dr. Smith receives compensation as a 
consultant for XYZ Company,” “Dr. Jones and Dr. Smith have 
financial holdings in ABC Company,” or “Dr. Jones owns a 
patent on the diagnostic device described in this report.” These 
statements acknowledging or denying conflicts of interest must 
be included in the manuscript under the heading Conflict of 
Interest. The Conflict of Interest disclosure appears in the cover 
letter, in the manuscript submission process and before the 
References section in the manuscript. 
 
Following the Conflict of Interest heading, there must be a 
listing for each author, detailing the professional services 
relevant to the submission. Neither the precise amount received 
from each entity nor the aggregate income from these sources 
needs to be provided. Professional services include any 
activities for which the individual is, has been, or will be 
compensated with cash, royalties, fees, stock or stock options in 
exchange for work performed, advice or counsel provided, or 
for other services related to the author’s professional 
knowledge and skills. This would include, but not necessarily 
be limited to, the identification of organizations from which the 
author received contracts or in which he or she holds an equity 
stake if professional services were provided in conjunction with 
the transaction. 
 
Examples of declarations are:  
 Conflict of interest. 
The authors declare no conflict of interest. 
 Conflict of interest. 
Dr Caron's work has been funded by the NIH. He has 
received compensation as a member of the scientific 
advisory board of Acadia Pharmaceutical and owns stock 
in the company. He also has consulted for Lundbeck and 
received compensation. Dr Rothman and Dr Jensen 
declare no potential conflict of interest. 
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Communication with the Media 
Material submitted must not be discussed with the media. We 
reserve the right to halt the consideration or publication of a 
paper if this condition is broken. If a paper is particularly 
newsworthy, the press release will be sent to our list of 
journalists in advance of publication with an embargo that 
forbids any coverage of the manuscript, or the findings of the 
manuscript, until the time and date clearly stated. Authors 
whose papers are scheduled for publication may also arrange 
their own publicity (for instance through their institution’s 
press offices), but they must strictly adhere to our press 
embargo and are advised to coordinate their own publicity 
with our press office. 
 
Communication between Scientists 
We do not wish to hinder communication between scientists. 
We ask you to communicate with other researchers as much as 
you wish, whether on a recognized community preprint server, 
by discussion at scientific meetings or by online collaborative 
sites such as wikis, but we do not encourage premature 
publication by discussion with the press (beyond a formal 
presentation, if at a conference).  
 
Pre- and Post-Submissions 
Authors are welcome to post pre-submission versions or the 
original submitted version of the manuscript on a personal 
blog, a collaborative wiki or a recognized preprint server (such 
as ArXiv) at any time (but not subsequent pre-accept versions 
that evolve due to the editorial process). 
 
For subscribed content, the accepted version of the manuscript, 
following the review process, may only be posted 6 months 
after the paper is published in an NPG journal. A publication 
reference and URL to the published version on the journal 
website must be provided on the first page of the postprint. The 
published version — copyedited and in the individual NPG 
journal format — may not be posted on any website or preprint 
server. 
 
For open access content published under a Creative Commons 
license, authors can replace the submitted version with the final 
published version at publication as long as a publication 
reference and URL to the published version on the journal 
website are provided. 
 
Authorship  
Requirements for all categories of articles should conform to 
the “Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals,” developed by the ICMJE 
(www.icmje.org).  
 
Each author must have contributed sufficiently to the 
intellectual content of the submission. The corresponding 
author should list all authors and their contributions to the 
work. Any changes to the author list after submission, such as a 
change in the order of the authors, or the deletion or addition of 
authors, must be approved by a signed letter from every 
author. The corresponding author must confirm that he or she 
has had full access to the data in the study and final 
responsibility for the decision to submit for publication. To 
qualify as a contributing author, one must meet all of the 
following criteria: 
1) Conceived and/or designed the work that led to the 
submission, acquired data, and/or played an important 
role in interpreting the results. 
2) Drafted or revised the manuscript. 
3) Approved the final version. 
 
Contributions by individuals who made direct contributions to 
the work but do not meet all of the above criteria should be 
noted in the Acknowledgments section of the manuscript.  
Medical writers and industry employees can be contributors. 
Their roles, affiliations, and potential conflicts of interest should 
be included in the author list or noted in the Acknowledgments 
and/or Contributors section concurrent with their contribution 
to the work submitted. Signed statements from any medical 
writers or editors declaring that they have given permission to 
be named as an author, as a contributor, or in the 
Acknowledgments section is also required.  Failure to 
acknowledge these contributors can be considered 
inappropriate, which conflicts with the journal’s editorial 
policy. 
 
Correspondence with the Journal 
One author is designated the contact author for matters arising 
from the manuscript (materials requests, technical comments 
and so on). It is this author's responsibility to inform all co-
authors of matters arising and to ensure such matters are dealt 
with promptly. Before submission, the corresponding author 
ensures that all authors are included in the author list, its order 
agreed upon by all authors, and are aware that the manuscript 
was submitted.  After acceptance for publication, proofs are e-
mailed to this corresponding author who should circulate the 
proof to all co-authors and coordinate corrections among them 
 
Plagiarism and Fabrication 
CrossCheck is a multi-publisher initiative to screen published 
and submitted content for originality. NPG Journals use 
CrossCheck to detect instances of overlapping and similar text 
in submitted manuscripts. To find out more about CrossCheck 
visit www.crossref.org/crosscheck.html. 
 
Plagiarism is when an author attempts to pass off someone 
else's work as his or her own. Duplicate publication, sometimes 
called self-plagiarism, occurs when an author reuses substantial 
parts of his or her own published work without providing the 
appropriate references. Minor plagiarism without dishonest 
intent is relatively frequent, for example, when an author reuses 
parts of an introduction from an earlier paper.  
 
If plagiarism is found, the journal will contact the author's 
institute and funding agencies. The paper containing the 
plagiarism will be marked on each page of the PDF and 
depending on the extent of the plagiarism, a published article 
may also be formally retracted. 
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Image Integrity and Standards 
Images submitted with a manuscript for review should be 
minimally processed (for instance, to add arrows to a 
micrograph). Authors should retain their unprocessed data and 
metadata files, as editors may request them to aid in 
manuscript evaluation. If unprocessed data is unavailable, 
manuscript evaluation may be stalled until the issue is 
resolved.  
 
A certain degree of image processing is acceptable for 
publication, but the final image must correctly represent the 
original data and conform to community standards. The 
guidelines below will aid in accurate data presentation at the 
image processing level:  
 Authors should list all image acquisition tools and image 
processing software packages used. Authors should 
document key image-gathering settings and processing 
manipulations in the Methods section. 
 Images gathered at different times or from different 
locations should not be combined into a single image, 
unless it is stated that the resultant image is a product of 
time-averaged data or a time-lapse sequence. If 
juxtaposing images is essential, the borders should be 
clearly demarcated in the figure and described in the 
legend. 
 Touch-up tools, such as cloning and healing tools in 
Photoshop, or any feature that deliberately obscures 
manipulations, is to be avoided. 
 Processing (such as changing brightness and contrast) is 
appropriate only when it is applied equally across the 
entire image and is applied equally to controls. Contrast 
should not be adjusted so that data disappear. Excessive 
manipulations, such as processing to emphasize one 
region in the image at the expense of others (for example, 
through the use of a biased choice of threshold settings), 
is inappropriate, as is emphasizing experimental data 
relative to the control. 
 
For gels and blots, positive and negative controls, as well as 
molecular size markers, should be included on each gel and 
blot – either in the main figure or an expanded data 
supplementary figure. The display of cropped gels and blots in 
the main paper is encouraged if it improves the clarity and 
conciseness of the presentation. In such cases, the cropping 
must be mentioned in the figure legend.  
 Vertically sliced gels that juxtapose lanes that were not 
contiguous in the experiment must have a clear 
separation or a black line delineating the boundary 
between the gels. 
 Cropped gels in the paper must retain important bands. 
 Cropped blots in the body of the paper should retain at 
least six band widths above and below the band. 
 High-contrast gels and blots are discouraged, as 
overexposure may mask additional bands. Authors 
should strive for exposures with gray backgrounds. 
Immunoblots should be surrounded by a black line to 
indicate the borders of the blot, if the background is faint. 
 For quantitative comparisons, appropriate reagents, 
controls and imaging methods with linear signal ranges 
should be used. 
 
Microscopy adjustments should be applied to the entire image. 
Threshold manipulation, expansion or contraction of signal 
ranges and the altering of high signals should be avoided. If 
‘pseudo-coloring’ and nonlinear adjustment (for example 
‘gamma changes’) are used, this must be disclosed. 
Adjustments of individual color channels are sometimes 
necessary on ‘merged’ images, but this should be noted in the 
figure legend. We encourage inclusion of the following with the 
final revised version of the manuscript for publication:  
 In the Methods section, specify the type of equipment 
(microscopes/objective lenses, cameras, detectors, filter 
model and batch number) and acquisition software used. 
Although we appreciate that there is some variation 
between instruments, equipment settings for critical 
measurements should also be listed. 
 The display lookup table (LUT) and the quantitative map 
between the LUT and the bitmap should be provided, 
especially when rainbow pseudo-color is used. It should 
be stated if the LUT is linear and covers the full range of 
the data. 
 Processing software should be named and manipulations 
indicated (such as type of deconvolution, three-
dimensional reconstructions, surface and volume 
rendering, 'gamma changes', filtering, thresholding and 
projection). 
 Authors should state the measured resolution at which an 
image was acquired and any downstream processing or 
averaging that enhances the resolution of the image. 
 
Human and Other Animal Experiments 
For primary research manuscripts reporting experiments on live 
vertebrates and/or higher invertebrates, the corresponding 
author must confirm that all experiments were performed in 
accordance with relevant guidelines and regulations. The 
manuscript must include in the Supplementary Information 
(methods) section (or, if brief, within of the article at an 
appropriate place), a statement identifying the institutional 
and/or licensing committee approving the experiments, 
including any relevant details regarding animal welfare, patient 
anonymity, drug side effects and informed consent. Sex and 
other characteristics of animals that may influence results must 
be described. Details of housing and husbandry must be 
included where they are likely to influence experimental 
results. Oncogenesis recommends following the ARRIVE 
reporting guidelines when documenting animal studies. 
 
For experiments involving human subjects, authors must 
identify the committee approving the experiments, and include 
with their submission a statement confirming that informed 
consent was obtained from all subjects.  
 
Biosecurity Policy 
The Editor may seek advice about submitted papers not only 
from technical reviewers but also on any aspect of a paper that 
raises concerns. These may include, for example, ethical issues 
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or issues of data or materials access. Occasionally, concerns 
may also relate to the implications to society of publishing a 
paper, including threats to security. In such circumstances, 
advice will usually be sought simultaneously with the technical 
peer-review process. As in all publishing decisions, the ultimate 
decision whether to publish is the responsibility of the editor of 
the journal concerned.  
 
Peer Review  
Manuscripts sent out for peer review are evaluated by at least 
one independent reviewer (often two or more). Authors are 
welcome to suggest independent reviewers to evaluate their 
manuscript, as well as request individuals or laboratories. All 
recommendations are considered, but it is at the Editor’s 
discretion their choice of reviewers. To expedite the review 
process, only papers that seem most likely to meet editorial 
criteria are sent for external review. Papers judged by the 
editors to be of insufficient general interest or otherwise 
inappropriate are rejected promptly without external review. 
The editors then make a decision based on the reviewers' 
evaluations:  
 Accept, with or without editorial revisions.  
 Revise, with the author addressing concerns raised by the 
reviewers before a final decision is reached. 
 Reject, but indicate to the authors that further work might 
justify a resubmission. 
 Reject outright, typically on grounds of specialist interest, 
lack of novelty, insufficient conceptual advance or major 
technical and/or interpretational problems. 
 
As of March 2015, Oncogenesis requires authors of papers that 
are sent for external review to include in their manuscripts 
relevant details about several elements of experimental and 
analytical design. This initiative aims to improve the 
transparency of reporting and the reproducibility of published 
results, focusing on elements of methodological information 
that are frequently poorly reported. Authors being asked to 
resubmit a manuscript will be asked to confirm that these 
elements are included by filling out a checklist that will be 
made available to the editor and reviewers. 
 
Anonymity and Confidentiality 
All details about submitted manuscripts are kept confidential 
and no comments are issued to outside parties or organizations 
about manuscripts under consideration or if they are rejected.  
Editors are restricted to making public comments on a 
published article’s content and their evaluation.   
 
We do not release reviewers' identities to authors, except when 
reviewers specifically ask to be identified.  
 
We ask reviewers not to identify themselves to authors without 
the editor's knowledge. If they wish to reveal their identities 
while the manuscript is under consideration, this should be 
done via the editor; if this is not practicable, we ask authors to 
inform the editor as soon as possible after the reviewer has 
revealed their identity. We deplore any attempt by authors to 
confront reviewers or try to determine their identities. Our own 
policy is to neither confirm nor deny any speculation about 
reviewers' identities, and we encourage reviewers to adopt a 
similar policy. 
 
Upon accepting an invitation to evaluate a manuscript, 
reviewers must keep the manuscript and associated data 
confidential, and not redistribute them without the journal’s 
permission.  If a reviewer asks a colleague to assist in assessing 
a manuscript, confidentiality must be ensured and their names 
must be provided to the journal with the final report.   
 
Selecting Peer Reviewers 
Reviewer selection is critical to the publication process, and we 
base our choice on many factors, based on expertise, reputation, 
and specific recommendations.  A reviewer may decline the 
invitation to evaluate a manuscript where there is a perceived 
conflict of interest (financial or otherwise).   
 
Correction and Retraction Process 
When an article is published online, it is part of the publication 
record; hence, this version must be preserved and changes to 
the paper must be made as a formal correction. If an error is 
noticed, an HTML (or full-text) version of the correction should 
be created and linked to the original article. 
 
Please note the following categories of corrections to published 
versions of peer-reviewed content: 
 Erratum. Notification of an important error made by the 
journal that affects the publication record or the scientific 
integrity of the paper, or the reputation of the authors, or 
of the journal. 
 Corrigendum. Notification of an important error made by the 
author that affects the publication record or the scientific 
integrity of the paper, or the reputation of the authors or 
the journal. 
 Retraction. Notification of invalid results. All co-authors 
must sign a retraction specifying the error and stating 
briefly how the conclusions are affected. 
 
Decisions about corrections are made by the Editor (sometimes 
with peer-reviewers' advice) and this sometimes involves 
author consultation. Requests to make corrections that do not 
affect the paper in a significant way or impair the reader's 
understanding of the contribution (a spelling mistake or 
grammatical error, for example) are not considered. 
 
In cases where co-authors disagree about a correction, the 
editors will take advice from independent peer-reviewers and 
impose the appropriate correction, noting the dissenting 
author(s) in the text of the published version. 
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FURTHER INFORMATION 
 
 
For inquiries related to submission requirements, please contact the editorial office. For inquiries related to advertising, 
permissions, papers in production or publishing a supplement, please contact the publisher’s office.  
 
